NCT06174792View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Adenomyosis
Interventions
DRUG

Drospirenone 4 MG

Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.

Trial Locations (1)

90123

Andrea Etrusco, Palermo

All Listed Sponsors
lead

University of Palermo

OTHER

NCT06174792 - Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis | Biotech Hunter | Biotech Hunter